Cancer Family
Neuroepithelial Neoplasm
CI-CAN-00000287Explore in graph →
Loading cancer entity…
Cancer Family
CI-CAN-00000287Explore in graph →
Variants & evidence
363 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PDGFRA Overexpression1 | ||||||||
| Dasatinib | High-Grade Glioma, NOS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7934Tumor cell line generated from pediatric high-grade glioma patient was found to have amplification of PDGFRA and FGF2. Gene expression of PDGFRA and FGF2 was found to be in the 99th percentile compare… (full text at CIViC) PMID 27582545 · Koschmann et al., 2016 · Open in CIViC | civic |
| PIK3CA Mutation1 | ||||||||
| Buparlisib | GlioblastomaCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID7072In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC) PMID 30715997 · Wen et al., 2019 · Open in CIViC | civic |
| PIK3R1 Mutation1 | ||||||||
| Buparlisib | GlioblastomaCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID7073In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC) PMID 30715997 · Wen et al., 2019 · Open in CIViC | civic |
| PLK1 OVEREXPRESSION1 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 2 | submitted | EID8005Kaplan-Meier analysis of PLK1 gene expression showed that elevated expression is significantly associated with shorter disease-free survival in GBM (p=9.1e-11). PMID 32180229 · Li et al., 2020 · Open in CIViC | civic |
| PMS2 K706FS*191 | ||||||||
| Nivolumab | GlioblastomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1214Two siblings (6 and 3.5 years) from nonconsanguineous parents were diagnosed with glioblastoma multiforme. Both tumors harbored TP53 mutations and lack of MGMT promoter hypermethylation as poor progno… (full text at CIViC) PMID 27001570 · Bouffet et al., 2016 · Open in CIViC | civic |
| POLE Mutation1 | ||||||||
| Pembrolizumab | GlioblastomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1861Case report of a patient with glioblastoma multiforme and POLE germline mutation. The patient was treated with pembrolizumab and lymphocyte infiltration was noted after resection of a spinal metastasi… (full text at CIViC) PMID 27683556 · Johanns et al., 2016 · Open in CIViC | civic |
| POLE R1233*1 | ||||||||
| (oncogenic) | High-Grade Glioma, NOS | Oncogenic | C | Does Not Support Oncogenicity | 3 | submitted | EID12524A 14-year old patient with bi-allelic PMS2 pathogenic germline variants (c.2 T>A, p.M1K and c.2521del, p.W841Gfs*10) and a diagnosis of constitutional mismatch repair deficiency (CMMRD) was diagnosed … (full text at CIViC) PMID 38773265 · Palova et al., 2024 · Open in CIViC | civic |
| NTRK1 ATRX + PTEN A121ENTRK1PTEN1 | ||||||||
| (diagnostic) | Glioma | Diagnostic | B | Supports Positive | 4 | submitted | EID11495Fusions involving neurotrophic tyrosine receptor kinase (NTRK) genes can promote gliomagenesis. While they varied in histological qualifications, nearly all the fused gliomas implicated a variant of t… (full text at CIViC) PMID 32665022 · Torre et al., 2020 · Open in CIViC | civic |
| PTEN Expression3 | ||||||||
| Dacomitinib | GlioblastomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID775In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII… (full text at CIViC) PMID 25939761 · Zahonero et al., 2015 · Open in CIViC | civic |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | GlioblastomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID77449 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort o… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC | civic |
| Erlotinib + | ||||||||
| PTEN Mutation3 | ||||||||
| (diagnostic) | GlioblastomaCURATED_BROADER | Diagnostic | C | Supports Positive | 2 | accepted | EID1931Rasheed et al. identified that PTEN mutations occur with significantly greater frequency in adults with high-grade gliomas (42 adult glioblastoma multiforme and 13 adult anaplastic astrocytoma) compar… (full text at CIViC) PMID 9331072 · Rasheed et al., 1997 · Open in CIViC | civic |
| Buparlisib | GlioblastomaCURATED_BROADER | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID7074In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC) PMID 30715997 · Wen et al., 2019 · Open in CIViC | civic |
| Nivolumab + PembrolizumabSubstitutes | Glioblastoma | |||||||
| PTEN R173C2 | ||||||||
| (diagnostic) | GlioblastomaCURATED_BROADER | Diagnostic | C | Supports N/A | 3 | rejected | EID1932Bostrom et al identified R173C in the tumor sample of 1 subject (out of 36 glioblastomas tested). By PCR mRNA expression of PTEN was assayed for tumor samples harboring PTEN variants. PTEN expression… (full text at CIViC) PMID 9426052 · Boström et al., 1998 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Diagnostic | C | Supports N/A | 2 | submitted | EID1933Fults et al identified 1 R173C mutation in a glioblastoma (of 45 tested). The tumor also displayed either all or partial LOH of 10q, there was no further resolution of the LOH size or mutational testi… (full text at CIViC) PMID 9499454 · Fults et al., 1998 · Open in CIViC | civic |
| PTEN R233*1 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Does Not Support Poor Outcome | 3 | accepted | EID343PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients. PMID 22479427 · Carico et al., 2012 · Open in CIViC | civic |
| PTPN11 Mutation1 | ||||||||
| (diagnostic) | Pilocytic Astrocytoma | Diagnostic | C | Supports Positive | 3 | submitted | EID7153Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Two alterations were found in the PTPN11 (aka SHP-2) gene, encoding a RAS-MAPK-related adaptor protein and phosphatase. Both alteratio… (full text at CIViC) PMID 23817572 · Jones et al., 2013 · Open in CIViC | civic |
| NTRK2 Fusion4 | ||||||||
| (oncogenic) | Low Grade Glioma | Oncogenic | C | Supports Oncogenicity | 1 | accepted | EID11437From a retrospective review of 38,095 tumor samples from 33,997 patients that underwent fusion screening at Memorial Sloan Kettering Cancer Center, 87 tumors were found to be positive for an NTRK1, NT… (full text at CIViC) PMID 31375766 · Solomon et al., 2020 · Open in CIViC | civic |
| 〃 | Polymorphous Low Grade Neuroepithelial Tumor of the Young | Oncogenic | C | Supports Oncogenicity | 1 | accepted | EID11438Molecular profiling of 13 patients with polymorphous low-grade neuroepithelial tumor of the young (PLNTY) at Mayo Clinic, identified 1 patient (15 yo female) with a QKI::NTRK2 (e6::e15) fusion. PMID 34363682 · Ida et al., 2021 · Open in CIViC | civic |
| 〃 | Pilocytic Astrocytoma | Oncogenic | C | Supports Oncogenicity | 1 | accepted | ||
| RB1 Loss-of-function1 | ||||||||
| Palbociclib | GlioblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID1595A panel of 21 glioblastoma cell lines harboring various mutations was treated with palbociclib. 16 of the cell lines with intact Rb showed decreased proliferation (bromodeoxyuridine incorporation, Brd… (full text at CIViC) PMID 20354191 · Michaud et al., 2010 · Open in CIViC | civic |
| ROS1 Overexpression1 | ||||||||
| Gefitinib | GlioblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 1 | submitted | EID1970Gefitinib resistant clones were subject to RNAseq and the expression of several genes was found to be upregulated. These genes are mainly tyrosine kinase receptors and include ROS1, DDR1 and PDGFRA. T… (full text at CIViC) PMID 25978031 · Aljohani et al., 2015 · Open in CIViC | civic |
| EGFR Fusion3 | ||||||||
| (oncogenic) | GlioblastomaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 1 | submitted | EID10934SEC61G::EGFR fusion identified in 4 out of 164 (2.4%) glioblastoma tumors (TCGA GBM working group, patient samples with pathobiology data). Fusion transcripts were confirmed by RNA-seq and were freque… (full text at CIViC) PMID 24120142 · Brennan et al., 2013 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 1 | submitted | EID10935TCGA pan-cancer data analysis of 9,624 tumors across 33 tumor types identified 25,664 fusions. Significantly associated gene fusion and increased expression level (by RNAseq compared to samples withou… (full text at CIViC) PMID 29617662 · Gao et al., 2018 · Open in CIViC | civic |
| Gefitinib | Childhood Ependymoma | Predictive | ||||||
| SLC12A2 OVEREXPRESSION1 | ||||||||
| Antisecretory Factor-enriched Egg Yolk Powder Supplement + TemozolomideCombination | GlioblastomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12689Antisecretory factor (AF) induction by the SPC diet or Salovum in GBM xenografts (GBM43, GBM6) reduced NKCC1-mediated chloride influx, chloride permeability, and blocked regulatory volume increase in … (full text at CIViC) PMID 29431617 · Ilkhanizadeh et al., 2018 · Open in CIViC | civic |
| TERT C228T2 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 2 | submitted | EID6934Evaluation of 25 Korean patients with primary glioblastomas, individuals with TERT promoter mutations (N=16) had worse overall survival (median 81.7 weeks [95% confidence interval (CI), 61.71–101.85])… (full text at CIViC) PMID 29344264 · Jeong et al., 2017 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Prognostic | D | Supports Poor Outcome | 2 | submitted | EID6935Surgical samples from 25 Korean patients with primary glioblastomas were disassociated for cell culture and evaluated for TERT promoter mutations (N=16 mutant, N=9 wildtype). All patients harbored the… (full text at CIViC) PMID 29344264 · Jeong et al., 2017 · Open in CIViC | civic |
| TERT C250T1 | ||||||||
| (oncogenic) | GlioblastomaCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | 4 | submitted | EID10331TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspo… (full text at CIViC) PMID 23955565 · Nonoguchi et al., 2013 · Open in CIViC | civic |
| TERT Promoter Mutation3 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID516In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27%… (full text at CIViC) PMID 23955565 · Nonoguchi et al., 2013 · Open in CIViC | civic |
| 〃 | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID6933In 50 patients with primary glioblastomas, patients without TERT promoter mutations (N=13, median 27 mo) survived longer than those harboring mutations (N=37, 14 mo; P = 0.01 by the log rank test; HR … (full text at CIViC) PMID 23530248 · Killela et al., 2013 · Open in CIViC | civic |
| 〃 | Childhood Low Grade Glioma | Prognostic | ||||||
| High1 | ||||||||
| (prognostic) | Low Grade Glioma | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID13062In patients with initially low-grade IDH-mutant gliomas previously treated with temozolomide, a high tumor mutational burden (TMB-high)/temozolomide-associated hypermutator phenotype was associated wi… (full text at CIViC) PMID 33823014 · Yu et al., 2021 · Open in CIViC | civic |
| TP53 M237I2 | ||||||||
| Unspecified therapy | GlioblastomaCURATED_BROADER | Predictive | C | Supports N/A | 5 | submitted | EID8064mutants in diverse tumor types activate different p53 target genes, but some may give rise to the same GoF phenotype. 12,13 For example, M237I, in glioblastoma, and R282W, in lung cancer, trigger chem… (full text at CIViC) PMID 29260852 · Silva et al., 2018 · Open in CIViC | civic |
| Temozolomide | GlioblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID7979The glioblastoma T98G cell line possesses a TP53 M237I variant. This cell line initially exhibited resistance to temozolomide treatment, but a five-fold increase in chemosensitivity (IC50 112.15 ug/ml… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC | civic |
| TP53 Mutation2 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID7976In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, 24 patients were found to have TP53 mutations at codons 175, 248, or 273. Patients with TP53 mutation were found t… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC | civic |
| Temozolomide | GlioblastomaCURATED_BROADER | Predictive | B | Supports Resistance | 3 | submitted | EID7978In a trial of 68 glioblastoma patients treated with either temozolomide or semustine, 24 patients were found to have TP53 mutations at codons 175, 248, or 273. Kaplan-Meier analysis of the 35 patients… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC | civic |
| TP53 P72R1 | ||||||||
| (prognostic) | OligodendrogliomaCURATED_BROADER | Prognostic | B | Does Not Support Poor Outcome | 2 | submitted | EID6932In the evaluation of 275 oligodendroglial tumors, the specific genotype at amino acid 72 of TP53 (Arg/Arg, Arg/Pro, or Pro/Pro) was not associated grade of malignancy (low- vs. high-grade, P = 0.650) … (full text at CIViC) PMID 17854663 · Idbaih et al., 2007 · Open in CIViC | civic |
| TP53 R273H1 | ||||||||
| Temozolomide | GlioblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID7980The glioblastoma U138 cell line possesses a TP53 R273H variant. This cell line initially exhibited resistance to temozolomide treatment, but a four-fold increase in chemosensitivity (IC50 127.79 ug/ml… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC | civic |
| NTRK1 Fusion2 | ||||||||
| Entrectinib | High-Grade Glioma, NOS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11851In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (4 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| Larotrectinib | Gliosarcoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID11746A 9-month-old boy with no family history of cancer presented with increased head circumference, and MRI demonstrated a solid lesion in the left frontal lobe. A subtotal surgical resection was performe… (full text at CIViC) PMID 35034013 · Mançano et al., 2022 · Open in CIViC | civic |
| VEGFA Overexpression1 | ||||||||
| Bevacizumab | GlioblastomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7013We found that high VEGF expression (mean positive area > 5,000 pixels/×400 field) was associated with increased likelihood of achieving radiographic response (P = .024; Table 2). PMID 18182667 · Sathornsumetee et al., 2008 · Open in CIViC | civic |
| VEGFA Overexpression of VEGF1211 | ||||||||
| Bevacizumab | GlioblastomaCURATED_BROADER | Predictive | B | Supports Resistance | 4 | submitted | EID9490In a clinical study including 12 patients already treated with bevacizumab, high levels of plasma VEGF-121 decrease the OS and the PFS (p = 0.0246 and p = 0.0295) compared to low level of expression. PMID 29747600 · Martini et al., 2018 · Open in CIViC | civic |
| NTRK2 Fusion1 | ||||||||
| (diagnostic) | Pilocytic Astrocytoma | Diagnostic | C | Supports Positive | 3 | submitted | EID7151Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Two new NTRK2 fusion events were identified in this study. These two NTRK2 fusion events, namely QKI-NTRK2 (2 of 96 samples) and NACC2… (full text at CIViC) PMID 23817572 · Jones et al., 2013 · Open in CIViC | civic |
| WDR12 OVEREXPRESSION1 | ||||||||
| (prognostic) | GlioblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID8004Expression of WDR12 was found to be significantly higher in tumour than normal tissue from TCGA LGG and GBM datasets. Kaplan-Meier analysis showed high WDR12 expression to be significantly associated … (full text at CIViC) PMID 32180229 · Li et al., 2020 · Open in CIViC | civic |
| WEE1 Overexpression2 | ||||||||
| Adavosertib | Diffuse Midline Glioma, H3 K27-Altered | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID7242Significant WEE1 protein overexpression was detected by IHC in VUMC-DIPG-1 tissue isolated from a patient's frontal lobe. Significant WEE1 protein levels were also found in E98-FM glioma cells. An i… (full text at CIViC) PMID 23270927 · Caretti et al., 2013 · Open in CIViC | civic |
| 〃 | Diffuse Midline Glioma, H3 K27-Altered | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7243Two mouse xenograft models were used: one of tumor cells from a genetically engineered mouse with a BRAF V600E mutation, and the other using a patient's DIPG cells (SF8628). SF8628 was found to have … (full text at CIViC) PMID 24305702 · Mueller et al., 2014 · Open in CIViC | civic |
| MAMLD1 Fusion1 | ||||||||
| (diagnostic) | Supratentorial Ependymoma YAP1 Fusion-Positive | Diagnostic | B | Supports Positive | 4 | accepted | EID11888A total of 15 pediatric patients with supratentorial ependymomas harboring YAP1::MAMLD1 fusions were reported. In all 15 cases, YAP1::MAMLD1 fusions were confirmed by RT-PCR and sequencing. In the ma… (full text at CIViC) PMID 30246434 · Andreiuolo et al., 2019 · Open in CIViC | civic |
Data updated 19 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| GlioblastomaCURATED_BROADER |
| Predictive |
| B |
| Supports Sensitivity Response |
| 3 |
| accepted |
EID1129Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment w… (full text at CIViC) PMID 16282176 · Mellinghoff et al., 2005 · Open in CIViC |
| civic |
| Predictive |
| B |
| Supports Resistance |
| 4 |
| submitted |
EID8176In this retrospective study of 66 GBM patients treated with PD-1 inhibitors (nivolumab or pembrolizumab) at recurrence, mutations in PTEN were frequently found among non-responders. Of 45 IDH1 wild-ty… (full text at CIViC) PMID 30742119 · Zhao et al., 2019 · Open in CIViC |
| civic |
EID11449Whole genome sequencing of 96 pilocytic astrocytomas by the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project identified QKI::NTRK2 (e6::e16) fusions in 2 cases (5 yo & 12 yo males)… (full text at CIViC) PMID 23817572 · Jones et al., 2013 · Open in CIViC |
| civic |
| 〃 | Anaplastic AstrocytomaALIAS | Oncogenic | D | Supports Oncogenicity | 3 | accepted | EID11450Authors demonstrated that a flag-tagged QKI::NTRK2 (e6::e16) fusion was able to transform Ink4a−/−/Arf−/− astrocytes, and these cells induced astrocytomas when injected intracranially into mice. QKI… (full text at CIViC) PMID 27402815 · Ni et al., 2017 · Open in CIViC | civic |
| Supports Sensitivity Response |
| 1 |
| submitted |
EID10933SEC61G::EGFR (5'UTR::e14) (5'-UTR of SEC61G and 3'-UTR of EGFR) was detected in ependymoma as a change sensitive to gefitinib (also confirmed by mice xenografts model). Screening of 16 ependymoma pati… (full text at CIViC) PMID 29092923 · Servidei et al., 2017 · Open in CIViC |
| civic |
| C |
| Supports Poor Outcome |
| 4 |
| accepted |
EID7188The aim of this Chinese study was to identify prognostic biomarkers for pediatric low-grade gliomas (PLGG). Approximately 300 patients were included. Using Sanger sequencing, mutations at TERT promote… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC |
| civic |